文献速递湿疹皮炎与荨麻疹

曲罗芦单抗治疗成人中重度特应性皮炎的眼部结膜炎分析

Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials.
PubMed 文献 · Br J Dermatol · 2021-11-28

本文基于五项随机安慰剂对照试验,分析曲罗芦单抗治疗成人中重度特应性皮炎(AD)患者至16周的结膜炎数据,共纳入2285例成人。基线AD更重、有过敏性结膜炎或特应性角结膜炎病史及特应性合并症较多者,结膜炎发生率在各治疗组中均升高。

要点

  • 基线AD更重、有过敏性结膜炎或特应性角结膜炎病史、特应性合并症较多者,结膜炎发生率更高。

核心结论

  • 曲罗芦单抗治疗与结膜炎发生率较安慰剂升高相关,但多数病例为轻度和一过性。

研究设计与样本

  • 汇总五项随机、安慰剂对照试验,纳入2285例成人中重度AD患者,观察至16周。
  • 采用Cochran-Mantel-Haenszel权重计算校正后的不良事件发生率。

主要发现

  • 无论治疗分组,基线AD更重、有过敏性结膜炎或特应性角结膜炎病史及特应性合并症较多者,结膜炎发生率均升高。

临床怎么用

  • 对接受曲罗芦单抗治疗的AD患者,应关注结膜炎发生,尤其基线AD较重或有过敏性结膜炎或特应性角结膜炎病史者。
  • 多数结膜炎为轻中度且可缓解,但需识别导致停药的事件。

局限性

  • 仅报告至第16周的事件。
  • 结膜炎及其病因的眼科医生确认有限。
  • 眼科治疗报告不充分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tralokinumab, a fully human IgG4 monoclonal antibody that specifically binds with high affinity to interleukin-13, effectively reduces moderate-to-severe atopic dermatitis (AD) when given every 2 weeks. The incidence of conjunctivitis is elevated vs. placebo, but severity and aetiology have not been examined. OBJECTIVE: To analyse conjunctivitis data recorded in five randomized, placebo-controlled trials of tralokinumab in adult patients with moderate-to-severe AD. METHODS: Overall, 2285 adults with AD were studied up to 16 weeks. Cochran-Mantel-Haenszel weights were applied to calculate the adjusted incidence of adverse events. RESULTS: The incidence of conjunctivitis was higher (7·5%) with tralokinumab than with placebo (3·2%). Most events were mild or moderate in severity, and 78·6% and 73·9% of events resolved during the trial in the tralokinumab and placebo groups, respectively. Two (1·4%) events led to the permanent discontinuation of tralokinumab. An increased incidence of conjunctivitis, regardless of treatment group, was associated with more severe baseline AD, and history of allergic conjunctivitis/atopic keratoconjunctivitis, as well as the number of atopic comorbidities. LIMITATIONS: This analysis reports events up to week 16 only, with limited confirmation of conjunctivitis and its aetiology by an ophthalmologist, and insufficient reporting of ophthalmic treatments. CONCLUSIONS: Treatment with tralokinumab was associated with an increased incidence of conjunctivitis vs. placebo, but these cases were mostly mild and transient.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Wollenberg A, Beck LA, de Bruin Weller M, et al. Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials. Br J Dermatol. 2021. PMID: 34637142. doi:10.1111/bjd.20810

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。